Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized evaluator-blinded crossover trial of SAR107375E for anticoagulation during maintenance hemodialysis
CTR20251499Phase 2Completed
- Sponsor
- Beijing Kelaibo Pharmaceutical Development
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAR107375E in chronic kidney disease (CKD), sponsored by Beijing Kelaibo Pharmaceutical Development. Started Jul 2025; status: completed.
02
Drugs
SAR107375E
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20251499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251499.